



**Proceeding**

Volume 3 Suppl 1 – March 2017  
DOI: 10.19080/AJPN.2017.03.555666

Acad J Ped Neonatol

Copyright © All rights are reserved by Ohoud AL-Zahrani

# Treatment of Congenital Hyperinsulinism with Long-Acting Release Octreotide in Saudi Children

**Ohoud AL-Zahrani, Afaf AL-Sagier, Yousef Sabeih and Bassam Bin Abbas**

*Department of Pediatrics, King Faisal Specialist Hospital and Research Centre, Saudi Arabia*

**Submission:** March 05, 2017; **Published:** March 28, 2017

**\*Corresponding author:** Department of Pediatrics/Section of Endocrinology and Diabetes, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia

## Introduction

Congenital hyperinsulinism (CHI) is the most common cause of persistent hypoglycemia in infancy. Multiple daily subcutaneous (SC) octreotide is the available medical treatment of diazoxide-unresponsive CHI.

## Objective

To assess the efficacy and safety of monthly intramuscular long-acting release (LAR) octreotide as a replacement for multiple daily s.c octreotide in the treatment of children with diazoxide unresponsive CHI.

## Methods

Fifteen CHI patients on multiple daily s.c octreotide were switched to monthly i.m (LAR) octreotide injections. Families were instructed to continue monitoring the blood glucose, and give s.c

octreotide as needed. Clinical and biochemical parameters were monitored before each i.m LAR octreotide injection. The patients were followed up for a minimum period of 6 months.

## Results

Twelve of our 15 patients (80%) were able to maintain their glucose level within the target and completely stopped the s.c octreotide injections (most of them were able to do so after the first i.m LAR octreotide injection), while 20% were clearly unable to stop or decrease their daily s.c octreotide injections. Apart from hyperglycemia in one patient, we did not encounter any serious complications.

## Conclusion

LAR octreotide is effective and safe in treating most of our CHI patients and simplified their medical care.



This work is licensed under Creative Commons Attribution 4.0 License  
DOI:10.19080/AJPN.2017.03.555666

### Your next submission with Juniper Publishers will reach you the below assets

- Quality Editorial service
- Swift Peer Review
- Reprints availability
- E-prints Service
- Manuscript Podcast for convenient understanding
- Global attainment for your research
- Manuscript accessibility in different formats  
( Pdf, E-pub, Full Text, Audio)
- Unceasing customer service

Track the below URL for one-step submission

<https://juniperpublishers.com/online-submission.php>